Ignite Creation Date:
2025-12-26 @ 5:23 PM
Ignite Modification Date:
2025-12-29 @ 12:46 AM
Study NCT ID:
NCT01013506
Status:
WITHDRAWN
Last Update Posted:
2013-05-23
First Post:
2009-11-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-08
Start Date Type:
None
Primary Completion Date:
2009-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-12
Completion Date Type:
ACTUAL
First Submit Date:
2009-11-12
First Submit QC Date:
None
Study First Post Date:
2009-11-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-05-22
Last Update Post Date:
2013-05-23
Last Update Post Date Type:
ESTIMATED